Hot Biotechnology Stock
We are a life sciences company committed to advancing personalized medicine and improving
patient outcomes through the development of innovative molecular diagnostic products that guide and target the most appropriate treatments. Through a comprehensive understanding of the genetics, biology and pathology of particular diseases, we have
pioneered and are developing molecular diagnostics and ...
more
We are a pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of
acute and chronic pain and pain related conditions. We operate a business model that focuses on the following:
more
We are a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Our most advanced drug candidate, lorcaserin hydrochloride,
or lorcaserin, is being investigated in a Phase 3 clinical trial program
for the treatment of obesity. We ...
more
Our website address is www.salix.com . We make available free of charge through
our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the
Securities and Exchange Commission.
more
Pall Corporation, a New York corporation incorporated in July 1946, and its subsidiaries (hereinafter collectively called the “Company” or referred to as “we” or “our” unless the context requires otherwise) is a leading supplier of integrated filtration, separation and purification technologies, principally made by the Company using its engineering capability, ...
more
,” and other sections of this Form 10-K. Our actual results or experience
could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “ Risk Factors ,” as well as those discussed elsewhere in this Form 10-K. You
should carefully consider that information before you make an investment decision.
more
We are a specialty pharmaceutical company focused on late-stage
development, commercialization and marketing of
over-the -counter, or
OTC, and prescription pharmaceuticals for the treatment of
respiratory disorders. We currently market three OTC products
under our Mucinex brand, one product under our Humibid brand,
two products under our Delsym brand, and four ...
more
")
to Coloplast for total consideration of $463,225,000, of which $456,137,500
would be in cash and $7,087,500 in non-cash consideration, and on June 2, 2006 we
completed this sale to Coloplast.
more
The information contained
in this section on business is qualified in its entirety by, and is subject to,
the detailed information, consolidated financial statements and notes thereto
contained elsewhere within this document.
more
Conduct and Ethics. The Board of Directors (the "Board") of
the
Company adopted the corporate governance policies and charters. Copies of the
following corporate governance documents are posted on our website, and are
available free of charge, at www.peregrineinc.com :
(1) Peregrine Pharmaceuticals, Inc. Code of Business Conduct and Ethics ...
more
This Annual Report on
Form 10-K
contains forward-looking statements that involve risks and
uncertainties relating to future events and the future financial
performance of Regeneron Pharmaceuticals, Inc., and actual
events or results may differ materially. These statements
concern, among other things, the possible success and
therapeutic applications of ...
more
The company develops therapeutic products for patient with chronic and life-threatening cardiovascular, cancer, and infectious diseases. It also offers telemedicine services for detection of cardiac arrhythmias and ischemic heart disease.
more
We
are a
biopharmaceutical company focused on the discovery and development of drugs
to
provide therapeutic intervention in treating human diseases at the cellular
level. As with all scientific endeavors, we face much trial and error, and
we
may fail at numerous stages along the way, which would inhibit us from
successfully developing, ...
more
We are a leading provider of
scientific instruments, consumables and services to the pharmaceutical, biomedical, academic research, environmental testing and general industrial markets, commonly referred to as the health sciences and photonics markets. We design, manufacture,
market and service products and systems within two businesses, each constituting a separate reporting segment:
more
Millipore is a global life science company that provides technologies, tools and services facilitating the discovery, development and production of new
therapeutic drugs, vaccines and detection tools, together with other applications. We serve the worldwide biotechnology, pharmaceutical and life science research industries by improving productivity and efficiency. We primarily sell consumable ...
more
